# NICHE (NCT03026140)

> Neoadjuvant Immune Checkpoint Inhibition and Novel IO Combinations in Early-stage Colon Cancer

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03026140
- Phase: PHASE2
- Status: RECRUITING
- Sponsor: The Netherlands Cancer Institute
- Conditions: Colon Carcinoma
- Interventions: Nivolumab; Ipilimumab; Celecoxib 200mg; BMS-986253; Relatlimab (BMS-986016)
- Enrollment: 353
- Primary outcome: Incidence of adverse events during the treatment and follow-up (safety)
- Primary outcome: Disease free survival
- Primary outcome: Major Pathological Response

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 3

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=niche-nct03026140